• Adicet Bio posted a net loss of $21.4 million, or $1.99 per share, for the second quarter ended June 30, 2026.
• R&D expense totaled $18.5 million; G&A expense was $3.9 million.
• Cash, cash equivalents and short-term investments were $118.2 million; funding runway expected into the second half of 2027.
• Phase 1 prula-cel update in lupus nephritis and SLE is now expected in 3Q 2026, with topline results anticipated in 3Q 2026.
• Regulatory filing for ADI-212 in mCRPC targeted for 3Q 2026, with Phase 1 enrollment expected to begin in 4Q 2026 pending clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001720580-26-000049), on August 05, 2026, and is solely responsible for the information contained therein.